Barclays Has Lowered Expectations for Bausch + Lomb (NYSE:BLCO) Stock Price

Bausch + Lomb (NYSE:BLCO - Get Free Report) had its target price cut by equities research analysts at Barclays from $19.00 to $16.00 in a report released on Monday,Benzinga reports. The brokerage presently has an "equal weight" rating on the stock. Barclays's price target would indicate a potential upside of 28.62% from the company's current price.

A number of other analysts also recently weighed in on BLCO. HC Wainwright reduced their target price on shares of Bausch + Lomb from $20.00 to $15.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Royal Bank of Canada dropped their price target on Bausch + Lomb from $18.00 to $17.00 and set an "outperform" rating for the company in a research report on Friday, April 4th. Needham & Company LLC reissued a "hold" rating on shares of Bausch + Lomb in a research note on Thursday, April 24th. Wells Fargo & Company lowered their price objective on Bausch + Lomb from $15.00 to $12.00 and set an "equal weight" rating for the company in a research note on Thursday, May 1st. Finally, Evercore ISI cut their target price on Bausch + Lomb from $19.00 to $15.50 and set an "outperform" rating on the stock in a research report on Thursday, May 1st. One analyst has rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $15.54.

Bausch + Lomb Stock Down 0.6%

BLCO stock traded down $0.07 during midday trading on Monday, hitting $12.44. The company's stock had a trading volume of 400,755 shares, compared to its average volume of 686,638. The firm's 50-day moving average is $11.87 and its 200-day moving average is $15.27. The company has a current ratio of 1.60, a quick ratio of 1.01 and a debt-to-equity ratio of 0.72. Bausch + Lomb has a 12 month low of $10.45 and a 12 month high of $21.69. The company has a market cap of $4.40 billion, a PE ratio of -13.67, a P/E/G ratio of 0.85 and a beta of 0.56.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last announced its earnings results on Wednesday, April 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.10). Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.35%. The business had revenue of $1.15 billion for the quarter, compared to the consensus estimate of $1.15 billion. During the same quarter last year, the firm posted $0.07 earnings per share. The business's quarterly revenue was up 3.5% compared to the same quarter last year. On average, equities research analysts forecast that Bausch + Lomb will post 0.74 earnings per share for the current fiscal year.

Insider Transactions at Bausch + Lomb

In related news, CEO Brent L. Saunders acquired 22,000 shares of the company's stock in a transaction that occurred on Thursday, May 22nd. The shares were bought at an average price of $11.28 per share, with a total value of $248,160.00. Following the completion of the transaction, the chief executive officer now directly owns 719,156 shares in the company, valued at $8,112,079.68. This trade represents a 3.16% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.76% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Deutsche Bank AG acquired a new stake in Bausch + Lomb in the first quarter valued at approximately $50,750,000. Alberta Investment Management Corp grew its stake in Bausch + Lomb by 8.6% during the 1st quarter. Alberta Investment Management Corp now owns 3,266,193 shares of the company's stock worth $47,360,000 after buying an additional 258,000 shares during the last quarter. Whitebox Advisors LLC increased its position in Bausch + Lomb by 16.1% during the 4th quarter. Whitebox Advisors LLC now owns 1,443,101 shares of the company's stock valued at $26,062,000 after buying an additional 199,856 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in Bausch + Lomb by 51.5% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,218,431 shares of the company's stock valued at $21,996,000 after buying an additional 414,138 shares in the last quarter. Finally, King Street Capital Management L.P. boosted its holdings in Bausch + Lomb by 55.2% in the fourth quarter. King Street Capital Management L.P. now owns 1,136,321 shares of the company's stock worth $20,522,000 after acquiring an additional 404,256 shares in the last quarter. Hedge funds and other institutional investors own 11.07% of the company's stock.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.